Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

130.00SEK
1:52pm GMT
Change (% chg)

0.05kr (+0.04%)
Prev Close
129.95kr
Open
130.00kr
Day's High
131.35kr
Day's Low
129.75kr
Volume
240,456
Avg. Vol
710,163
52-wk High
143.80kr
52-wk Low
107.40kr

Select another date:

Wed, Oct 25 2017

UPDATE 1-Sobi to scale up in North America as Q3 beats expectations

Oct 25 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.

BRIEF-Swedish Orphan Biovitrum says Alprolix approved for use in Saudi Arabia‍​

* Alprolix approved for treatment of Hemofili B in Saudi Arabia.‍​ Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)

BRIEF-Sobi raises outlook as Q3 core profit beats expectations

* Swedish orphan biovitrum says ‍sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)​

Select another date: